Bavituximab + Nivolumab enhances tumor Immune response in a 3D Ex Vivo System of Lung Cancer Patients

Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer Patient Derived Tumors with Negative PD-L1 Expression.

InternationalAssociation for the Study of Lung Cancer (IASLC) 16th WorldConference on Lung Cancer.  09/06/2015 to09/09/2015. Denver, CO, USA.

DOWNLOAD poster